Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?
- PMID: 28245351
- DOI: 10.1002/art.40082
Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?
Comment on
-
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.Arthritis Rheumatol. 2017 Jun;69(6):1144-1153. doi: 10.1002/art.40070. Epub 2017 May 3. Arthritis Rheumatol. 2017. PMID: 28217871 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

